FDA 483 - Aaron C. Ermel, MD - September 12, 2025

An FDA inspection of Aaron C. Ermel, MD, a clinical investigator in Indianapolis, IN, revealed a significant deviation from an investigational plan. A subject was improperly randomized and dosed despite meeting an exclusion criterion, indicating a failure to follow study protocol.